

Benedetto Bruno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5888920/publications.pdf>

Version: 2024-02-01

291
papers

11,229
citations

25034

57
h-index

37204

96
g-index

293
all docs

293
docs citations

293
times ranked

8926
citing authors

#	ARTICLE	IF	CITATIONS
1	A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma. <i>New England Journal of Medicine</i> , 2007, 356, 1110-1120.	27.0	479
2	Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. <i>Blood</i> , 2003, 102, 3447-3454.	1.4	382
3	European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications. <i>Haematologica</i> , 2015, 100, 1254-1266.	3.5	289
4	Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1874.	7.4	274
5	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. <i>Journal of Clinical Oncology</i> , 2008, 26, 4912-4920.	1.6	257
6	Comparison of Outcomes of HLA-Matched Related, Unrelated, or HLA-Haploidentical Related Hematopoietic Cell Transplantation following Nonmyeloablative Conditioning for Relapsed or Refractory Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 1279-1287.	2.0	251
7	Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. <i>Blood</i> , 2011, 117, 3025-3031.	1.4	247
8	Treatment for Acute Myelogenous Leukemia by Low-Dose, Total-Body, Irradiation-Based Conditioning and Hematopoietic Cell Transplantation From Related and Unrelated Donors. <i>Journal of Clinical Oncology</i> , 2006, 24, 444-453.	1.6	243
9	Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2005, 23, 3819-3829.	1.6	214
10	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	1.6	204
11	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	1.6	197
12	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2010, 28, 2859-2867.	1.6	191
13	European Myeloma Network recommendations on the evaluation and treatment of newly diagnosed patients with multiple myeloma. <i>Haematologica</i> , 2014, 99, 232-242.	3.5	185
14	Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Blood</i> , 2007, 110, 2744-2748.	1.4	156
15	International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4521-4530.	1.6	156
16	Early CPAP prevents evolution of acute lung injury in patients with hematologic malignancy. <i>Intensive Care Medicine</i> , 2010, 36, 1666-1674.	8.2	152
17	Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability. <i>Blood</i> , 2010, 115, 3671-3677.	1.4	151
18	American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2039-2051.	2.0	146

#	ARTICLE	IF	CITATIONS
19	Adenovirus infection in hematopoietic stem cell transplantation: effect of ganciclovir and impact on survival. <i>Biology of Blood and Marrow Transplantation</i> , 2003, 9, 341-352.	2.0	144
20	Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1525-1536.	10.7	143
21	Incidence and Outcome of Invasive Fungal Diseases after Allogeneic Stem Cell Transplantation: A Prospective Study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 872-880.	2.0	141
22	Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders. <i>Biology of Blood and Marrow Transplantation</i> , 2008, 14, 246-255.	2.0	133
23	Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. <i>Blood</i> , 2015, 125, 2855-2864.	1.4	132
24	Bone marrow versus mobilized peripheral blood stem cells in haploidentical transplants using posttransplantation cyclophosphamide. <i>Cancer</i> , 2018, 124, 1428-1437.	4.1	131
25	Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect. <i>Leukemia</i> , 2012, 26, 520-526.	7.2	129
26	Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2021, 39, 1223-1233.	1.6	127
27	Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. <i>Blood</i> , 2004, 103, 790-795.	1.4	124
28	Effector $\hat{3}\hat{1}$ T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma. <i>Leukemia</i> , 2005, 19, 664-670.	7.2	119
29	Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. <i>Blood</i> , 2011, 117, 6721-6727.	1.4	113
30	The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation. <i>Leukemia</i> , 2009, 23, 1131-1138.	7.2	111
31	From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives. <i>Haematologica</i> , 2018, 103, 197-211.	3.5	110
32	Post-transplant cyclophosphamide <i>versus</i> anti-thymocyte globulin as graft- <i>versus</i> -host disease prophylaxis in haploidentical transplant. <i>Haematologica</i> , 2017, 102, 401-410.	3.5	109
33	Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting. <i>Blood</i> , 2009, 113, 3383-3391.	1.4	106
34	Factors Associated With Outcomes in Allogeneic Hematopoietic Cell Transplantation With Nonmyeloablative Conditioning After Failed Myeloablative Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2006, 24, 4150-4157.	1.6	104
35	Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey. <i>Clinical Infectious Diseases</i> , 2017, 65, 1884-1896.	5.8	103
36	Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. <i>Annals of Oncology</i> , 2008, 19, 1160-1165.	1.2	101

#	ARTICLE	IF	CITATIONS
37	Secondary failure of platelet recovery after hematopoietic stem cell transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 154-162.	2.0	100
38	Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid. <i>Blood</i> , 2007, 110, 921-927.	1.4	98
39	Nonmyeloablative allogeneic haematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: a multicentre experience. <i>British Journal of Haematology</i> , 2008, 143, 395-403.	2.5	97
40	Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. <i>Blood</i> , 2009, 113, 3375-3382.	1.4	92
41	Non-myeloablative allografting from human leucocyte antigen-identical sibling donors for treatment of acute myeloid leukaemia in first complete remission. <i>British Journal of Haematology</i> , 2003, 120, 281-288.	2.5	90
42	ADENOVIRUS NEPHRITIS IN HEMATOPOIETIC STEM-CELL TRANSPLANTATION. <i>Transplantation</i> , 2004, 77, 1049-1057.	1.0	89
43	Melphalan 200 mg/m ² versus melphalan 100 mg/m ² in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. <i>Blood</i> , 2010, 115, 1873-1879.	1.4	87
44	Characterization of Monoclonal Antibodies That Recognize Canine CD34. <i>Blood</i> , 1998, 91, 1977-1986.	1.4	85
45	Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Haematologica</i> , 2018, 103, 1317-1328.	3.5	84
46	Unrelated Donor Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cell Transplantation after Nonmyeloablative Conditioning: The Effect of Postgrafting Mycophenolate Mofetil Dosing. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 454-465.	2.0	83
47	Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma. <i>Leukemia</i> , 2014, 28, 1885-1891.	7.2	83
48	European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias. <i>Leukemia</i> , 2018, 32, 1883-1898.	7.2	81
49	Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation. <i>British Journal of Haematology</i> , 2015, 171, 239-246.	2.5	80
50	Adoptive immunotherapy in canine mixed chimeras after nonmyeloablative hematopoietic cell transplantation. <i>Blood</i> , 2000, 95, 3262-3269.	1.4	79
51	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies after Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 949-957.	2.0	79
52	Allogeneic Stem Cell Transplantation in Multiple Myeloma Relapsed after Autograft: A Multicenter Retrospective Study Based on Donor Availability. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 617-626.	2.0	75
53	Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 388-397.	2.0	72
54	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1418-1424.	2.0	62

#	ARTICLE	IF	CITATIONS
55	Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. <i>Frontiers in Immunology</i> , 2017, 8, 1444.	4.8	62
56	New drugs for treatment of multiple myeloma. <i>Lancet Oncology</i> , The, 2004, 5, 430-442.	10.7	59
57	Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party. <i>Leukemia</i> , 2016, 30, 2047-2054.	7.2	59
58	The Use of Granulocyte Colony-Stimulating Factor During Retroviral Transduction on Fibronectin Fragment CH-296 Enhances Gene Transfer Into Hematopoietic Repopulating Cells in Dogs. <i>Blood</i> , 1999, 94, 2287-2292.	1.4	57
59	Hematopoietic cell transplantation from HLA-identical sibling donors after low-dose radiation-based conditioning for treatment of CML. <i>Leukemia</i> , 2005, 19, 990-997.	7.2	57
60	Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. <i>Haematologica</i> , 2005, 90, 278-9.	3.5	57
61	Novel targeted drugs for the treatment of multiple myeloma: from bench to bedside. <i>Leukemia</i> , 2005, 19, 1729-1738.	7.2	55
62	Donor age determines outcome in acute leukemia patients over 40 undergoing haploidentical hematopoietic cell transplantation. <i>American Journal of Hematology</i> , 2018, 93, 246-253.	4.1	52
63	Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. <i>European Journal of Haematology</i> , 2006, 76, 273-277.	2.2	51
64	Treatment of CMV infection after allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2016, 9, 585-596.	2.2	51
65	Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. <i>Leukemia and Lymphoma</i> , 2010, 51, 1424-1443.	1.3	49
66	The Role of Positron Emission Tomography with 18F-Fluorodeoxyglucose Integrated with Computed Tomography in the Evaluation of Patients with Multiple Myeloma Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1068-1073.	2.0	46
67	Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1615-1620.	2.0	46
68	Exposure to myeloma cell lysates affects the immune competence of dendritic cells and favors the induction of Tr1-like regulatory T cells. <i>European Journal of Immunology</i> , 2005, 35, 1155-1163.	2.9	45
69	The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 888.	4.8	45
70	Allogeneic haematopoietic cell transplantation after nonmyeloablative conditioning in patients with T cell and natural killer cell lymphomas. <i>British Journal of Haematology</i> , 2010, 150, 170-178.	2.5	44
71	The impact of HLA matching on outcomes of unmanipulated haploidentical HSCT is modulated by GVHD prophylaxis. <i>Blood Advances</i> , 2017, 1, 669-680.	5.2	43
72	Improved gene transfer into canine hematopoietic repopulating cells using CD34-enriched marrow cells in combination with a gibbon ape leukemia virus pseudotype retroviral vector. <i>Gene Therapy</i> , 1999, 6, 966-972.	4.5	42

#	ARTICLE	IF	CITATIONS
73	Prognostic relevance of 'early-onset' graft-versus-host disease following non-myeloablative haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2005, 129, 381-391.	2.5	41
74	Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 809-817.	2.0	41
75	Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation to Treat Patients with Poor-Risk, Relapsed, or Refractory Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 423-432.	2.0	40
76	Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. <i>Annals of Oncology</i> , 2016, 27, 2251-2257.	1.2	40
77	Impact of ABO incompatibility on patients' outcome after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia - a report from the Acute Leukemia Working Party of the EBMT. <i>Haematologica</i> , 2017, 102, 1066-1074.	3.5	40
78	Low-Dose Total Body Irradiation and Fludarabine Conditioning for HLA Class I-Mismatched Donor Stem Cell Transplantation and Immunologic Recovery in Patients with Hematologic Malignancies: A Multicenter Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 384-394.	2.0	39
79	Extending Postgrafting Cyclosporine Decreases the Risk of Severe Graft-versus-Host Disease after Nonmyeloablative Hematopoietic Cell Transplantation. <i>Transplantation</i> , 2006, 81, 818-825.	1.0	38
80	Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. <i>Haematologica</i> , 2006, 91, 837-9.	3.5	38
81	Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide. <i>Leukemia</i> , 2019, 33, 230-239.	7.2	36
82	Combined differentiating therapy for myelodysplastic syndromes: A phase II study. <i>Leukemia Research</i> , 1996, 20, 867-876.	0.8	34
83	Immuno-oncologic Approaches: CAR-T Cells and Checkpoint Inhibitors. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 471-478.	0.4	34
84	Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma. <i>Leukemia</i> , 2016, 30, 1211-1214.	7.2	33
85	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2388-2397.	2.0	33
86	Extracellular vesicles as potential biomarkers of acute graft-vs-host disease. <i>Leukemia</i> , 2018, 32, 765-773.	7.2	32
87	CD34+ SELECTED BONE MARROW GRAFTS ARE RADIOPROTECTIVE AND ESTABLISH MIXED CHIMERISM IN DOGS GIVEN HIGH DOSE TOTAL BODY IRRADIATION1. <i>Transplantation</i> , 1999, 68, 338-344.	1.0	32
88	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
89	Long-term survival of 1338 MM patients treated with tandem autologous vs. autologous-allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2020, 55, 1810-1816.	2.4	31
90	Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m ²). <i>Leukemia</i> , 2004, 18, 133-138.	7.2	30

#	ARTICLE	IF	CITATIONS
91	Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2017, 52, 1637-1642.	2.4	30
92	Use of eltrombopag in aplastic anemia in Europe. <i>Annals of Hematology</i> , 2019, 98, 1341-1350.	1.8	30
93	Impact of donor age and kinship on clinical outcomes after T-cell replete haploidentical transplantation with PT-Cy. <i>Blood Advances</i> , 2020, 4, 3900-3912.	5.2	30
94	Kaposi's sarcoma triggered by endogenous HHV-8 reactivation after non-myeloablative allogeneic haematopoietic transplantation. <i>European Journal of Haematology</i> , 2006, 76, 342-347.	2.2	29
95	Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies. <i>Haematologica</i> , 2014, 99, 1611-1617.	3.5	29
96	Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2020, 55, 393-399.	2.4	29
97	Dramatic Increase of Tacrolimus Plasma Concentration During Topical Treatment for Oral Graft-Versus-Host Disease. <i>Transplantation</i> , 2006, 82, 1113-1115.	1.0	28
98	Very Low Rate of Readmission after an Early Discharge Outpatient Model for Autografting in Multiple Myeloma Patients: An Italian Multicenter Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1026-1032.	2.0	28
99	Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT. <i>British Journal of Haematology</i> , 2018, 182, 418-422.	2.5	28
100	Recombinant interferon- γ inhibits the in vitro proliferation of human myeloma cells. <i>British Journal of Haematology</i> , 1994, 86, 726-732.	2.5	27
101	EX VIVO EXPANSION OF CANINE DENDRITIC CELLS FROM CD34+ BONE MARROW PROGENITOR CELLS1. <i>Transplantation</i> , 2000, 70, 1437-1442.	1.0	27
102	Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. <i>Annals of Hematology</i> , 2014, 93, 1391-1400.	1.8	27
103	Minimal residual disease status predicts outcome of acute myeloid leukaemia patients undergoing T-cell replete haploidentical transplantation. An analysis from the Acute Leukaemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). <i>British Journal of Haematology</i> , 2018, 183, 411-420.	2.5	27
104	European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma. <i>Haematologica</i> , 2021, 106, 2054-2065.	3.5	27
105	Italian consensus conference for the outpatient autologous stem cell transplantation management in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2016, 51, 1032-1040.	2.4	26
106	Unrelated donor haematopoietic cell transplantation after non-myeloablative conditioning for patients with high-risk multiple myeloma. <i>European Journal of Haematology</i> , 2007, 78, 330-337.	2.2	25
107	Multicenter Experience Using Total Lymphoid Irradiation and Antithymocyte Globulin as Conditioning for Allografting in Hematological Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1600-1607.	2.0	25
108	Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post-Transplantation Cyclophosphamide Graft-versus-Host Disease Prophylaxis. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1549-1554.	2.0	25

#	ARTICLE	IF	CITATIONS
109	Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 932-940.	2.0	25
110	Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. <i>Haematologica</i> , 2019, 104, 380-391.	3.5	25
111	Real-time polymerase chain reaction in multiple myeloma. <i>Experimental Hematology</i> , 2002, 30, 529-536.	0.4	24
112	Bortezomib Plus Dexamethasone Followed by Escalating Donor Lymphocyte Infusions for Patients with Multiple Myeloma Relapsing or Progressing after Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 424-428.	2.0	24
113	Comparable survival using a CMV-matched or a mismatched donor for CMV+ patients undergoing T-replete haplo-HSCT with PT-Cy for acute leukemia: a study of behalf of the infectious diseases and acute leukemia working parties of the EBMT. <i>Bone Marrow Transplantation</i> , 2018, 53, 422-430.	2.4	24
114	Timing of Post-Transplantation Cyclophosphamide Administration in Haploidentical Transplantation: A Comparative Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1915-1922.	2.0	24
115	Fludarabine and 2-Cy TBI is Superior to 2Â°Cy TBI as Conditioning for HLA-Matched Related Hematopoietic Cell Transplantation: A Phase III Randomized Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1340-1347.	2.0	23
116	Intermediate-Dose Melphalan (100 mg/m ²)/Bortezomib/Thalidomide/Dexamethasone and Stem Cell Support in Patients with Refractory or Relapsed Myeloma. <i>Clinical Lymphoma and Myeloma</i> , 2006, 6, 475-477.	1.4	22
117	Nonmyeloablative allogeneic stem cell transplantation in elderly patients with hematological malignancies: Results from the GITMO (Gruppo Italiano Trapianto Midollo Osseo) multicenter prospective clinical trial. <i>American Journal of Hematology</i> , 2007, 82, 863-866.	4.1	22
118	Eltrombopag for the Treatment of Refractory Pure RBC Aplasia after Major ABO Incompatible Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1765-1770.	2.0	22
119	Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT. <i>Journal of Hematology and Oncology</i> , 2019, 12, 68.	17.0	22
120	Related and unrelated nonmyeloablative hematopoietic stem cell transplantation for malignant diseases. <i>International Journal of Hematology</i> , 2002, 76, 184-189.	1.6	21
121	Prospective qualitative and quantitative non-invasive evaluation of intestinal acute GVHD by contrast-enhanced ultrasound sonography. <i>Bone Marrow Transplantation</i> , 2013, 48, 1421-1428.	2.4	21
122	Ruxolitinib in steroid refractory graft-vs.-host disease: a case report. <i>Journal of Hematology and Oncology</i> , 2016, 9, 67.	17.0	21
123	Tâ€cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3â€TD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. <i>American Journal of Hematology</i> , 2018, 93, 736-744.	4.1	21
124	Impact of New Drugs on the Long-Term Follow-Up of Upfront Tandem Autograftâ€Allograft in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 189-193.	2.0	21
125	Allogeneic Hematopoietic Cell Transplantation from Unrelated Donors in Multiple Myeloma: Study from the Italian Bone Marrow Donor Registry. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 940-948.	2.0	20
126	Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 1211-1219.	4.1	20

#	ARTICLE	IF	CITATIONS
127	Time to first disease progression, but not β_2 -microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy. <i>Cancer</i> , 2007, 110, 824-829.	4.1	19
128	The use of γ ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors. <i>American Journal of Hematology</i> , 2015, 90, E117-21.	4.1	19
129	Long-term follow-up of a retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic transplantation from matched related donors in myelodysplastic syndromes. <i>Bone Marrow Transplantation</i> , 2017, 52, 1107-1112.	2.4	19
130	Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 698-703.	2.0	19
131	Letemovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience. <i>Frontiers in Oncology</i> , 2021, 11, 740079.	2.8	19
132	Incidence of HLA Loss in a Global Multicentric Cohort of Post-Transplantation Relapses: Results from the Hlaloss Collaborative Study. <i>Blood</i> , 2018, 132, 818-818.	1.4	19
133	Autologous hematopoietic progenitor cell transplantation for multiple myeloma through an outpatient program. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1449-1462.	3.1	18
134	Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 857-872.	3.1	18
135	Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades. <i>Haematologica</i> , 2021, 106, 1599-1607.	3.5	18
136	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. <i>Blood</i> , 2019, 134, 693-693.	1.4	18
137	Impact of conditioning intensity on outcomes of haploidentical stem cell transplantation for patients with acute myeloid leukemia 45 years of age and over. <i>Cancer</i> , 2019, 125, 1499-1506.	4.1	17
138	Long-Term Follow-Up of a Donor versus No-Donor Comparison in Patients with Multiple Myeloma in First Relapse after Failing Autologous Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 406-409.	2.0	16
139	Extracellular Vesicles After Allogeneic Hematopoietic Cell Transplantation: Emerging Role in Post-Transplant Complications. <i>Frontiers in Immunology</i> , 2020, 11, 422.	4.8	16
140	Post-transplant cyclophosphamide in one-antigen mismatched unrelated donor transplantation versus haploidentical transplantation in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 562-571.	2.4	16
141	Retinoic acid inhibits the growth of human myeloma cells in vitro. <i>British Journal of Haematology</i> , 1995, 89, 555-560.	2.5	15
142	Multicyclic, dose-intensive chemotherapy supported by hemopoietic progenitors in refractory myeloma patients. <i>Bone Marrow Transplantation</i> , 1997, 19, 23-29.	2.4	15
143	Role of Allogeneic Stem Cell Transplantation in Multiple Myeloma. <i>Seminars in Hematology</i> , 2009, 46, 158-165.	3.4	14
144	European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. <i>Leukemia and Lymphoma</i> , 2010, 51, 2006-2011.	1.3	14

#	ARTICLE	IF	CITATIONS
145	Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients. <i>Leukemia</i> , 2012, 26, 1779-1785.	7.2	14
146	Current use and potential role of procalcitonin in the diagnostic work up and follow up of febrile neutropenia in hematological patients. <i>Expert Review of Hematology</i> , 2017, 10, 543-550.	2.2	14
147	Impact of total body irradiation vs chemotherapy-based myeloablative conditioning on outcomes of haploidentical hematopoietic cell transplantation for acute myelogenous leukemia. <i>American Journal of Hematology</i> , 2020, 95, 1200-1208.	4.1	14
148	Interferon- β in Multiple Myeloma. <i>Leukemia and Lymphoma</i> , 1995, 18, 215-219.	1.3	13
149	Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2214-2219.	2.0	13
150	Immunomodulatory and clinical effects of daratumumab in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 191, e28-e32.	2.5	13
151	<p>Optimal Delivery of Follow-Up Care After Allogeneic Hematopoietic Stem-Cell Transplant: Improving Patient Outcomes with a Multidisciplinary Approach</p>. <i>Journal of Blood Medicine</i> , 2020, Volume 11, 141-162.	1.7	13
152	Biomarkers for Early Complications of Endothelial Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Do They Have a Potential Clinical Role?. <i>Frontiers in Immunology</i> , 2021, 12, 641427.	4.8	13
153	GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥ 60 Years from 2000 to 2017: Improvements and Criticisms. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 96.e1-96.e11.	1.2	13
154	Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. <i>Bone Marrow Transplantation</i> , 2018, 53, 1304-1310.	2.4	12
155	Comparative evaluation of biological human leukocyte antigen DPB1 mismatch models for survival and graft-versus-host disease prediction after unrelated donor hematopoietic cell transplantation. <i>Haematologica</i> , 2020, 105, e186-e189.	3.5	12
156	Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives. <i>Frontiers in Bioscience - Landmark</i> , 2019, 24, 1284-1315.	3.0	12
157	Eltrombopag for the Treatment of Aplastic Anemia in Europe. <i>Blood</i> , 2018, 132, 1304-1304.	1.4	12
158	Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes. <i>Blood</i> , 2001, 98, 3447-3455.	1.4	11
159	Impact of anti-thymocyte globulin dose for graft-versus-host disease prophylaxis in allogeneic hematopoietic cell transplantation from matched unrelated donors: a multicenter experience. <i>Annals of Hematology</i> , 2021, 100, 1837-1847.	1.8	11
160	Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method. <i>Experimental Hematology</i> , 2009, 37, 728-738.	0.4	10
161	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <i>Bone Marrow Transplantation</i> , 2020, 55, 172-181.	2.4	10
162	Biomarkers for acute and chronic graft versus host disease: state of the art. <i>Expert Review of Hematology</i> , 2021, 14, 79-96.	2.2	10

#	ARTICLE	IF	CITATIONS
163	Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 2194-2202.	2.4	10
164	The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. <i>Bone Marrow Transplantation</i> , 2022, 57, 384-390.	2.4	10
165	<i>T-richoderma</i> species fungemia after high-dose chemotherapy and autologous stem cell transplantation: a case report. <i>Transplant Infectious Disease</i> , 2014, 16, 653-657.	1.7	9
166	Association between Thymic Function and Allogeneic Hematopoietic Stem Cell Transplantation Outcome: Results of a Pediatric Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1099-1105.	2.0	9
167	Rescue treatment with eltrombopag in refractory cytopenias after allogeneic stem cell transplantation. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072096191.	2.5	9
168	Purified canine CD34+Lin- marrow cells transduced with retroviral vectors give rise to long-term multi-lineage hematopoiesis. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 543-551.	2.0	8
169	Recurrent Plasmacytomas after Allografting in a Patient with Multiple Myeloma. <i>Case Reports in Medicine</i> , 2012, 2012, 1-5.	0.7	8
170	Are orange lollies effective in preventing nausea and vomiting related to dimethyl sulfoxide? A multicenter randomized trial. <i>Supportive Care in Cancer</i> , 2014, 22, 2417-24.	2.2	8
171	Long-term follow-up of allogeneic stem cell transplantation in relapsed/refractory Hodgkin lymphoma. <i>Bone Marrow Transplantation</i> , 2017, 52, 1208-1211.	2.4	8
172	Counting circulating endothelial cells in allo-HSCT: an ad hoc designed polychromatic flowcytometry-based panel versus the CellSearch System. <i>Scientific Reports</i> , 2019, 9, 87.	3.3	8
173	CMV retinitis in a stem cell transplant recipient treated with foscarnet intravitreal injection and CMV specific immunoglobulins. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072097565.	2.5	8
174	Antiemetic prophylaxis in patients undergoing hematopoietic stem cell transplantation: a multicenter survey of the Gruppo Italiano Trapianto Midollo Osseo (GITMO) transplant programs. <i>Annals of Hematology</i> , 2020, 99, 867-875.	1.8	8
175	Improving prognostic assignment in older adults with multiple myeloma using acquired genetic features, clonal hemopoiesis and telomere length. <i>Leukemia</i> , 2021, . .	7.2	8
176	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf</i>	1.3	7
177	â€Real-lifeâ€™ report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Bone Marrow Transplantation</i> , 2018, 53, 58-63.	2.4	7
178	Association of aplastic anaemia and lymphoma: a report from the severe aplastic anaemia working party of the European Society of Blood and Bone Marrow Transplantation. <i>British Journal of Haematology</i> , 2019, 184, 294-298.	2.5	7
179	Use of Bone Marrow or Peripheral Blood Stem Cell Grafts in Non T Cell Depleted Haploidentical Transplants Using Post-Transplant Cyclophosphamide, an ALWP-EBMT Analysis. <i>Blood</i> , 2016, 128, 1165-1165.	1.4	7
180	Risk Factors for Early Cytomegalovirus Reactivation and Impact of Early Cytomegalovirus Reactivation on Clinical Outcomes after T Cell-Replete Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 169.e1-169.e9.	1.2	7

#	ARTICLE	IF	CITATIONS
181	Reduced intensity versus non-myeloablative conditioning regimen for haploidentical transplantation and post-transplantation cyclophosphamide in complete remission acute myeloid leukemia: a study from the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1421-1427.	2.4	7
182	Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma. <i>Bone Marrow Transplantation</i> , 2015, 50, 511-516.	2.4	6
183	An update on the treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. <i>Expert Review of Hematology</i> , 2019, 12, 937-945.	2.2	6
184	FLAI induction regimen in elderly patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 3339-3340.	1.3	6
185	Donor Lymphocyte Infusions After Allogeneic Stem Cell Transplantation in Acute Leukemia: A Survey From the Gruppo Italiano Trapianto Midollo Osseo (GITMO). <i>Frontiers in Oncology</i> , 2020, 10, 572918.	2.8	6
186	Early Diagnosis of Neutropenic Enterocolitis by Bedside Ultrasound in Hematological Malignancies: A Prospective Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4277.	2.4	6
187	Allogeneic Genetically Modified T Cells (HSV-TK) As Adjunctive Treatment in Haploidentical Hematopoietic Stem-Cell Transplantation (haplo-HSCT) of Adult Patients with High-Risk Hematological Malignancies: A Pair-Matched Analysis from the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2016, 128, 672-672.	1.4	6
188	Genomic and Immune Signatures Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone (D-KRd). <i>Blood</i> , 2021, 138, 325-325.	1.4	6
189	Management of carbapenem-resistant <i>K. pneumoniae</i> in allogeneic stem cell transplant recipients: the Turin bundle. <i>New Microbiologica</i> , 2017, 40, 143-145.	0.1	6
190	Generation of anti-tumour activity by OKT3-stimulation in multiple myeloma: in vitro inhibition of autologous haemopoiesis. <i>British Journal of Haematology</i> , 1994, 87, 494-502.	2.5	5
191	Bortezomib after Allografting in Multiple Myeloma: Association between Neurotoxicity and Cyclosporine Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 497-499.	2.0	5
192	Netupitant-palonosetron to prevent chemotherapy-induced nausea and vomiting in multiple myeloma patients receiving high-dose melphalan and autologous stem cell transplantation. <i>Annals of Hematology</i> , 2020, 99, 2197-2199.	1.8	5
193	Nilotinib in steroid-refractory cGVHD: prospective parallel evaluation of response, according to NIH criteria and exploratory response criteria (GITMO criteria). <i>Bone Marrow Transplantation</i> , 2020, 55, 2077-2086.	2.4	5
194	Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 296-304.	0.4	5
195	Comparison of Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning with HLA-Matched Related (MRD), Unrelated (URD), and Related Haploidentical (Haplo) Donors for Relapsed or Refractory Hodgkin Lymphoma (HL).. <i>Blood</i> , 2007, 110, 173-173.	1.4	5
196	Immune Reconstitution and Thymic Function After Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. <i>Blood</i> , 2010, 116, 1254-1254.	1.4	5
197	Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease After Haploidentical Stem Cell Transplantation and Post-Transplant Cyclophosphamide. <i>Frontiers in Immunology</i> , 2021, 12, 816231.	4.8	5
198	Identification of a new HLA-DRB1 allele in three members of an Italian family. <i>Tissue Antigens</i> , 2004, 64, 210-212.	1.0	4

#	ARTICLE	IF	CITATIONS
199	Allogeneic stem cell transplant for adults with myelodysplastic syndromes: relevance of pre-transplant disease status. <i>Leukemia and Lymphoma</i> , 2014, 55, 863-869.	1.3	4
200	Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 347-364.	3.1	4
201	New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 821-836.	3.1	4
202	Haplo-identical allografting with post-transplant cyclophosphamide in high-risk patients. <i>Annals of Hematology</i> , 2018, 97, 2205-2215.	1.8	4
203	Biomarkers of Acute Graft-Versus-Host Disease: Surface Antigens and Micro Rnas in Extracellular Vesicles. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S232.	2.0	4
204	The stepchild in myeloma treatments: is allogeneic transplantation not so bad after all?. <i>Haematologica</i> , 2019, 104, 222-225.	3.5	4
205	Allelic HLA Matching and Pair Origin Are Favorable Prognostic Factors for Unrelated Hematopoietic Stem Cell Transplantation in Neoplastic Hematologic Diseases: An Italian Analysis by the Gruppo Italiano Trapianto di Cellule Staminali e Terapie Cellulari, Italian Bone Marrow Donor Registry, and Associazione Italiana di Immunogenetica e Biologia dei Trapianti. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 406.e1-406.e11.	1.2	4
206	Prognostic factors for neutrophil engraftment after haploidentical cell transplantation with PT-Cy in patients with acute myeloid leukemia in complete remission, on behalf of the ALWP-EBMT. <i>Bone Marrow Transplantation</i> , 2021, 56, 1842-1849.	2.4	4
207	COVID-19 in a Post-transplant Heart Recipient Who Developed Aggressive Lymphoma: A Biphasic Course During Rituximab Treatment. <i>HemaSphere</i> , 2021, 5, e592.	2.7	4
208	Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients with De Novo and Secondary Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 149-149.	1.4	4
209	Insights into high-risk multiple myeloma from an analysis of the role of PHF19 in cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 380.	8.6	4
210	Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 258.e1-258.e8.	1.2	4
211	Identification of a new allele, HLA-DRB5*0113, through three different molecular biology techniques+. <i>Tissue Antigens</i> , 2006, 67, 427-429.	1.0	3
212	Impact of Allogeneic Stem Cell Transplantation on Testicular and Sexual Function. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 182.e1-182.e8.	1.2	3
213	Response assessment to venetoclax in relapsed/refractory chronic lymphocytic leukemia by ultrasonography. <i>Leukemia Research</i> , 2021, 100, 106488.	0.8	3
214	A Prospective Cross-Sectional Study on the Comparison of Ultrasound Assessment vs. Palpation in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy. <i>Journal of Clinical Medicine</i> , 2022, 11, 3206.	2.4	3
215	Allogeneic Hematopoietic Cell Transplantation (HCT) in the Eighth Decade of Life: How Much Does Age Matter?. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S98-S99.	2.0	2
216	Late-onset hepatic veno-occlusive disease after allografting: report of two cases with atypical clinical features successfully treated with defibrotide.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2017, 10, 2018001.	1.3	2

#	ARTICLE	IF	CITATIONS
217	Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease (GVHD): A Study on Behalf of the Acute Leukemia Working Party of EBMT.. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S242-S243.	2.0	2
218	Organ Stiffness in the Work-Up of Myelofibrosis and Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Journal of Clinical Medicine</i> , 2020, 9, 2149.	2.4	2
219	Editorial: CART-Cell Therapies in Hematologic Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 588134.	2.8	2
220	Tandem Autologous-Autologous Vs. Autologous-Allogeneic Transplantation for Newly Diagnosed Multiple Myeloma: Pooled Analysis of 1,338 Patients from Four Trials with Long-Term Follow up. <i>Blood</i> , 2019, 134, 259-259.	1.4	2
221	Nonmyeloablative Unrelated Donor Hematopoietic Cell Transplantation (HCT) for Patients (pts) with Poor Risk, Relapsed or Refractory Multiple Myeloma.. <i>Blood</i> , 2004, 104, 2756-2756.	1.4	2
222	The Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) Predicts Survival and Non-Relapse Mortality in Lymphoma and Myeloma Patients Undergoing Reduced-Intensity or Non-Myeloablative Allogeneic Stem Cell Transplantations .. <i>Blood</i> , 2008, 112, 2144-2144.	1.4	2
223	Allogeneic Hematopoietic Cell Transplantation (HCT) after Nonmyeloablative Conditioning for Patients (pts) Aged ≥60 Years.. <i>Blood</i> , 2008, 112, 2162-2162.	1.4	2
224	Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT). <i>Blood</i> , 2010, 116, 2364-2364.	1.4	2
225	Long-Term Follow up of a Comparison of Non-Myeloablative Allografting with Autografting for Newly Diagnosed Myeloma. <i>Blood</i> , 2010, 116, 525-525.	1.4	2
226	HLA Disparities Impact on Outcomes after Unmanipulated Haploidentical Hematopoietic Stem Cells Transplantation (HaploSCT) in Acute Leukemia: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2015, 126, 399-399.	1.4	2
227	Hispanic or Latin American Ancestry Is Associated with a Similar Genomic Profile and a Trend Toward Inferior Outcomes in Newly Diagnosed Multiple Myeloma As Compared to Non-Hispanic White Patients in the Multiple Myeloma Research Foundation (MMRF) CoMMpasstudy. <i>Blood</i> , 2021, 138, 4117-4117.	1.4	2
228	Bortezomib treatment followed by a second non-myeloablative allogeneic stem cell transplant in two previously autografted patients with multiple myeloma relapse. <i>Haematologica</i> , 2005, 90, 861-2.	3.5	2
229	"ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS". <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2010, 2, e2010013.	1.3	1
230	Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 96-103.	0.4	1
231	The outcome of two or more HLA loci mismatched unrelated donor hematopoietic cell transplantation for acute leukemia: an ALWP of the EBMT study. <i>Bone Marrow Transplantation</i> , 2021, 56, 20-29.	2.4	1
232	Decades of Progress in Allogeneic Stem Cell Transplantation for Multiple Myeloma. <i>Hemato</i> , 2021, 2, 89-102.	0.6	1
233	Legionellosis after hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2555-2566.	2.4	1
234	Early Diagnosis of Neutropenic Enterocolitis by Ultrasound Sonography.. <i>Blood</i> , 2009, 114, 4742-4742.	1.4	1

#	ARTICLE	IF	CITATIONS
235	A Relapse Risk Score to Predict Acute Myeloid Leukemia Relapse After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation Based on Pre-Transplant Variables.. Blood, 2010, 116, 3450-3450.	1.4	1
236	Allogeneic Bone Marrow Transplantation From Unrelated Donors in Multiple Myeloma: A Study from the Italian Bone Marrow Transplantation Donor Registry. Blood, 2011, 118, 2009-2009.	1.4	1
237	Intensified Chemo-Immunotherapy Including up-Front Autologous or Allogeneic Stem Cell Transplantation (SCT) for Young Patients with Newly Diagnosed Peripheral T-Cell Lymphomas: Final Results of a Phase II Multicenter Prospective Clinical Trial. Blood, 2012, 120, 1984-1984.	1.4	1
238	Immunophenotypic Response After Allografting In Multiple Myeloma. Blood, 2013, 122, 3371-3371.	1.4	1
239	Role of Allogeneic Stem Cell Transplantation (AlloSCT) in Patients Affected By Peripheral T-Cell Lymphomas (PTCL): No Difference in Outcome Between Patients Allografted at Diagnosis and in First Chemosensitive Relapse. Blood, 2014, 124, 2574-2574.	1.4	1
240	Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma. Blood, 2014, 124, 44-44.	1.4	1
241	Randomized Trial of Busulfan with Cyclophosphamide Versus Busulfan with Fludarabine As Preparative Regimen to Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia: A Study from the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood, 2014, 124, 727-727.	1.4	1
242	A Comparative Study of Biosimilar Filgrastim Versus Originator G-CSF for CD34+ Cells Mobilization and Autografting in Hematological Malignancies. Blood, 2016, 128, 2183-2183.	1.4	1
243	Extracellular Vesicles as Potential Biomarker for Acute Graft-Versus-Host-Disease. Blood, 2016, 128, 2239-2239.	1.4	1
244	Unmanipulated Haploidentical Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Post Transplant Cyclophosphamide Anti-Gvhd Prophylaxis. Blood, 2016, 128, 3475-3475.	1.4	1
245	Survival after Relapse Following Tandem Allogeneic Vs. Tandem Autologous Hematopoietic Cell Transplantation (HCT) for Myeloma (MM). Blood, 2016, 128, 833-833.	1.4	1
246	Non-Myeloablative Allografting from HLA-Identical Sibling Donors for Treatment of CML.. Blood, 2004, 104, 2316-2316.	1.4	1
247	Relapse Risk after Nonmyeloablative Hematopoietic Cell Transplantation for Malignant Diseases.. Blood, 2005, 106, 703-703.	1.4	1
248	Nonmyeloablative Unrelated Donor (URD) Hematopoietic Cell Transplantation (HCT) for the Treatment of Patients (pts) with Poor-Risk, Relapsed or Refractory Multiple Myeloma.. Blood, 2005, 106, 2893-2893.	1.4	1
249	Unrelated Donor Hematopoietic Cell Transplantation after Non-Myeloablative Conditioning for Patients with High Risk Multiple Myeloma.. Blood, 2006, 108, 3158-3158.	1.4	1
250	Long-Term Follow Up of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT).. Blood, 2007, 110, 1662-1662.	1.4	1
251	Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study. Blood, 2014, 124, 421-421.	1.4	1
252	A Prospective Multicenter Study of Nonmyeloablative Conditioning with TBI or Fludarabine/TBI for HLA-Matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies with Post Grafting Immunosuppression with Tacrolimus and Mycophenolate Mofetil: 10-Year Experience. Blood, 2015, 126, 1949-1949.	1.4	1

#	ARTICLE	IF	CITATIONS
253	Graft-Versus-Leukemia Effect after Haplo-Identical Stem Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with AML- No Association with Graft-Versus-Host Disease: A Study on Behalf of the Acute Leukemia Working Party of EBMT. <i>Blood</i> , 2018, 132, 4586-4586.	1.4	1
254	Post-Transplant Cyclophosphamide, Abatacept, and Short Course of Tacrolimus Combination (CAST) Is Safe and Seems Highly Effective in Preventing Graft-Versus-Host Disease Following Haploidentical Peripheral Blood Stem Cell Transplantation. <i>Blood</i> , 2021, 138, 3906-3906.	1.4	1
255	<i>Post-Transplant High Dose Cyclophosphamide and Bortezomib As Graft-Versus-Host Disease Prophylaxis Following Allogeneic Hematopoietic Stem Cell Transplantation</i>. <i>Blood</i> , 2021, 138, 3892-3892.	1.4	1
256	Letermovir Prophylaxis Versus Pre-Emptive Therapy for Cytomegalovirus after Hematopoietic Stem-Cell Transplantation. <i>Blood</i> , 2021, 138, 4861-4861.	1.4	1
257	Unifying the Definition of High-Risk in Multiple Myeloma. <i>Blood</i> , 2021, 138, 2714-2714.	1.4	1
258	Impact of donor kinship on non-T-cell depleted haploidentical stem cell transplantation with post transplantation cyclophosphamide for acute leukemia: From the ALWP of the EBMT. <i>Bone Marrow Transplantation</i> , 2022, 57, 1260-1268.	2.4	1
259	Management of Myeloma: An Italian Perspective. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, S82-S86.	0.4	0
260	Reply to A. Gratwohl. <i>Journal of Clinical Oncology</i> , 2011, 29, e484-e484.	1.6	0
261	Allogeneic transplantation for multiple myeloma: yes, no or maybe?. <i>Bone Marrow Transplantation</i> , 2016, 51, 506-507.	2.4	0
262	ABO Mismatching and Haploidentical Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia—a Report from the ALWP of the EBMT. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S36-S37.	2.0	0
263	Upfront Tandem Auto-Allo Transplant in Multiple Myeloma: Long-Term Follow-Up and Impact of “New Drugs” at Relapse. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, e66-e67.	0.4	0
264	Minimal Residual Disease Status in Acute Myeloid Leukemia Patients Undergoing T-Cell Replete Haploidentical Transplantation. an Analysis From the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (Ebmt). <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S106-S107.	2.0	0
265	Promising Role of Extracellular Vesicles as Biomarkers of Acute Graft-vs.-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S196.	2.0	0
266	Outcomes of Acute Myelogenous Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide: Impact of Total Body Irradiation Versus Chemotherapy-Based Myeloablative Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S110.	2.0	0
267	Incidence of Invasive Aspergillosis in Allogeneic Stem Cell Transplantation Patients: An Italian Prospective Multicenter Study.. <i>Blood</i> , 2004, 104, 5057-5057.	1.4	0
268	Exhaled Nitric Oxide (eNO) and Pulmonary Function after Total Body Irradiation (TBI) Based Non Myeloablative Conditioning Regimens and Allogeneic Hematopoietic Cell Transplant.. <i>Blood</i> , 2005, 106, 5311-5311.	1.4	0
269	Evolving Indications for Hematopoietic Stem Cell Transplantation in Multiple Myeloma and Other Plasma Cell Disorders. <i>Cancer Treatment and Research</i> , 2009, 144, 317-355.	0.5	0
270	Tandem Auto/AlloHCT for Newly Diagnosed Multiple Myeloma (MM) Patients.. <i>Blood</i> , 2008, 112, 1130-1130.	1.4	0

#	ARTICLE	IF	CITATIONS
271	Allogeneic Stem Cell Transplantation (Allo-SCT) Following a Reduced-Intensity Conditioning (RIC) Regimen in Relapsed Peripheral T-Cell Lymphomas (PTCL): Results at 4 Year of Median Follow-up.. Blood, 2009, 114, 875-875.	1.4	0
272	Outcomes Following Relapse of Non-Hodgkin Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) After Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors. Blood, 2010, 116, 1292-1292.	1.4	0
273	Role of Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation In Patients with Multiple Myeloma Relapsing After Autograft: a Donor Versus No Donor Analysis. Blood, 2010, 116, 3534-3534.	1.4	0
274	High Response Rates to Bortezomib-Dexamethasone Followed by Donor Lymphocyte Infusions in Patients with Multiple Myeloma Relapsing After Allogeneic Stem Cell Transplantation: Results of a Multicentric Prospective Phase II Study. Blood, 2011, 118, 828-828.	1.4	0
275	Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose. Blood, 2012, 120, 354-354.	1.4	0
276	A Case-Matched Analysis Comparing Lenalidomide After Autologous or After Allogeneic Stem Cell Transplantation Demonstrates a Survival Advantage in Allografted Myeloma Patients. Blood, 2012, 120, 1960-1960.	1.4	0
277	High Rates of Prolonged Molecular Remissions After Tandem Autologous-Nonmyeloablative Allografting in Newly Diagnosed Myeloma. Blood, 2012, 120, 4204-4204.	1.4	0
278	Efficacy of Reduced-Intensity Allogeneic Stem Cell Transplant after Brentuximab Vedotin in Patients with Hodgkin Lymphoma Relapsed after Autologous Transplant. Blood, 2014, 124, 5943-5943.	1.4	0
279	Multicolor Flowcytometry Analysis of Hematopoietic Stem and Progenitor Cells Subsets Among Basal and Mobilized Peripheral CD34+ Cells. Blood, 2014, 124, 5117-5117.	1.4	0
280	Hematopoietic Cell Transplantation Comorbidity Index As Prognostic Variable in Patients with Invasive Fungal Infections. Blood, 2015, 126, 5526-5526.	1.4	0
281	Allogeneic Stem Cell Transplantation Versus B-Cell-Receptor Inhibitors in 17p Deletion and/or Refractory Chronic Lymphocytic Leukemia: A Retrospective Comparative Analysis of 'Real Life' Approaches to High Risk Patients, on Behalf of Rete Ematologica Lombarda (REL) and Gruppo Italiano Trapianto Di Midollo Osseo (GITMO). Blood, 2016, 128, 4695-4695.	1.4	0
282	Prolonged Follow-up Confirmed a Role for Upfront Tandem Auto-Allo Transplant in Multiple Myeloma Also in the Era of New Drugs. Blood, 2016, 128, 3469-3469.	1.4	0
283	Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome. Blood, 2016, 128, 53-53.	1.4	0
284	Donor Age Determines Outcome in Acute Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation. Blood, 2017, 130, 850-850.	1.4	0
285	High Resolution Donor/Recipient HLA Matching Level in Unrelated Hematopoietic Stem Cell Transplantation and Impact on the Transplant Outcome: The Italian Experience on Behalf of GITMO, IBMDR and Aibt. Blood, 2018, 132, 4642-4642.	1.4	0
286	Permissive HLA-DPB1 Mismatch and Survival after Unrelated Donor Allogeneic Stem Cell Transplantation for Hematological Malignancies: A Comparative Analysis of Different Immunogenetic Models on 422 Patients from GITMO and IBMDR. Blood, 2018, 132, 482-482.	1.4	0
287	Single Cell Analysis of Circulating Endothelial Cells in Allogeneic Hematopoietic Stem Cell Transplant; To Whom Do They Belong: Host or Donor?. Blood, 2019, 134, 4885-4885.	1.4	0
288	Outcome of Two Loci Mismatched (â‰¥6/8) Unrelated Donor Hematopoietic Cell Transplantation for Acute Leukemia: ALWP of the EBMT Study. Blood, 2019, 134, 4604-4604.	1.4	0

#	ARTICLE	IF	CITATIONS
289	Multiomic Mapping of Copy Number and Structural Variation on Chromosome 1 (Chr1) Highlights Multiple Recurrent Disease Drivers. <i>Blood</i> , 2021, 138, 721-721.	1.4	0
290	Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	0
291	Impact of Dose Adjusted Post-Transplant Cyclophosphamide after Allogeneic Stem Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, S462-S463.	1.2	0